Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
September 19 2017 - 8:30AM
Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies based on the Arcelis® precision immunotherapy
technology platform, will hold a conference call to discuss an
update on the ongoing Phase 3 ADAPT clinical trial evaluating
Rocapuldencel-T for the treatment of metastatic renal cell
carcinoma (mRCC) that was recently presented at the European
Society for Medical Oncology (ESMO) 2017 Congress. Robert Figlin,
MD, Professor and Chairman, Division of Hematology and Oncology at
Cedars Sinai Medical Center and co-principal investigator for the
ADAPT trial, delivered the oral presentation at the ESMO Conference
and will participate in the call.
Conference Call and Webcast Details
Argos executive management will host the
conference call beginning at 4:30 p.m. Eastern Time on Wednesday,
September 20th. To participate by telephone, please dial the
following numbers:
Domestic:
(855)
433-0930
International: (484)
756-4271
The conference ID number is 88556647.
A live and archived audio webcast with the
accompanying slide and video presentations will be accessible
through the Investors section of the Company's website at
www.argostherapeutics.com, and will remain available on the
Company's website for twelve (12) months following the call.
In addition, the slides presented by Dr. Figlin
at the ESMO Conference and a video in which Dr. Figlin discusses
the trial will be posted to Argos’ website at the time of the
call.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies for the treatment of cancer and infectious diseases
using its Arcelis® technology platform. Argos' most advanced
product candidate, Rocapuldencel-T, is being evaluated in the
pivotal ADAPT Phase 3 clinical trial for the treatment of
metastatic renal cell carcinoma (mRCC). In addition,
Rocapuldencel-T is being studied in a Phase 2
investigator-initiated clinical trial as neoadjuvant therapy for
renal cell carcinoma (RCC). Argos is also developing a separate
Arcelis®-based product candidate, AGS-004, for the treatment of
human immunodeficiency virus (HIV), which is currently being
evaluated in combination with vorinostat, a latency-reversing drug,
in an investigator-initiated Phase 2 clinical trial aimed at HIV
eradication in adult patients. Funding for the development of
AGS-004 has been provided by the National Institutes of Health, the
National Institute of Allergy and Infectious Diseases, and the
Collaboratory of Research for AIDS Eradication.
Forward Looking Statements
Any statements in this press release about
Argos' future expectations, plans and prospects, including
statements about the ADAPT trial and the interim data from the
trial, the clinical development of Argos' product candidates and
future expectations and plans and prospects for Argos and other
statements containing the words "believes," "anticipates,"
"estimates," "expects," "intends," "plans," "predicts," "projects,"
"targets," "may," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including whether Argos' cash resources
will be sufficient to fund its continuing operations for the period
anticipated; whether preliminary or interim clinical data will be
indicative of the final data from a clinical trial; whether results
obtained in clinical trials will be indicative of results obtained
in future clinical trials; whether Argos' product candidates will
advance through the clinical trial process on a timely basis;
whether the results of such trials will warrant submission for
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether Argos' product
candidates will receive approval from regulatory agencies on a
timely basis or at all; whether, if product candidates obtain
approval, they will be successfully distributed and marketed;
whether Argos can successfully establish commercial manufacturing
operations on a timely basis or at all; and other factors discussed
in the "Risk Factors" section of Argos' Form 10-Q for the quarter
ended June 30, 2017, which is on file with the SEC, and in other
filings Argos makes with the SEC from time to time. In addition,
the forward-looking statements included in this press release
represent Argos' views as of the date hereof. Argos anticipates
that subsequent events and developments will cause Argos' views to
change. However, while Argos may elect to update these
forward-looking statements at some point in the future, Argos
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Argos' views as of any date subsequent to the date
hereof.
Investor contact: Richard Katz, MD, MBA Chief Financial Officer
Argos Therapeutics, Inc. 919-287-6315
rkatz@argostherapeutics.com
Media Contact: Adam Daley Berry & Company Public Relations
212.253.8881 adaley@berrypr.com